Ophthalmology Drugs Market is Forecast to Grow at $26 billion in 2022 Ophthalmology Drugs Market is Forecast to 2022 | Page 5

4.4.1 Failure Rate 44
4.4.2 Clinical Trial Duration 48
4.4.3 Clinical Trial Size 52
4.4.4 Aggregate Clinical Program Size 56
4.4.5 Conclusion 60
5 Multi-Scenario Market Forecast to 2022 61
5.1 Overall Market Size 61
5.2 Generic Penetration 62
5.3 Revenue Forecast by Molecular Target 63
5.3.1 Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors) 63
5.3.2 Antihistamines (H1 Receptor) 64
5.3.3 Anti-inflammatories (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor) 65
5.3.4 IOP-Lowering (Prostaglandins/Beta Blockers/Rho Kinase Signaling Pathway) 66
5.3.5 Assessment of Key Pipeline Products 66
6 Company Analysis and Positioning 72
6.1 Revenue and Market Share Analysis by Company 73
6.1.1 Novartis - Will Pipeline Product Approvals Offset the Patent Expiry of Lucentis? 78
6.1.2 Bayer - Growing Revenues for Eylea Set to Increase Bayer’s Revenue 79
6.1.3 Regeneron - Growing Revenues for Eylea Will Make it the Top Selling Ophthalmology Drug 80
6.1.4 Roche - Gradual Decline in Revenues Due to Lucentis Patent Expiries and Uptake of Generics
81
6.1.5 Ophthotech - Pipeline Product Approval will Result in Blockbuster Status Within the Forecast
Period 82
6.1.6 Spark Therapeutics - Pipeline Product Approval to Resulting in Large Revenues in a Short
Space of Time 83
Follow Us: